Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
По алфавиту
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- L
- M
- N
- O
- P
- Q
- R
- S
- T
- V
- W
- X
- Y
- Z
- І
- А
- Б
- В
- Г
- Д
- Е
- Ж
- З
- И
- К
- Л
- М
- Н
- О
- П
- Р
- С
- Т
- У
- Ф
- Х
- Ц
- Ч
- Ш
- Щ
- Э
- Ю
- Я
- Весь список
Warning: mb_strpos(): Empty delimiter in /var/www/u1363561/data/www/biotech.spb.ru/wp-content/plugins/code-snippets/php/snippet-ops.php(581) : eval()’d code(4) : eval()’d code on line 13
T Robak
[Biological properties and therapeutic use of interleukin 2 (IL-2)]Postepy Hig Med Dosw. 1995;49(3):367-93.
Tanigawa T, Tanaka H, Kano F, Ueda H, Inafuku S.
Nasal hemangiopericytoma successfully treated with a combination of rIL-2 and extranasal approaches.J Surg Case Rep. 2017 Oct 20;2017(10):rjx202.
Tao Jiang, Caicun Zhou & Shengxiang Ren. 
PDF
ONCOIMMUNOLOGY. — 2016. — VOL. 5, NO. 6, e1163462 (10 pages)
Tenorio EP, Fernández J, Castellanos C, Olguín JE, Saavedra R.
CD4+ Foxp3+ regulatory T cells mediate Toxoplasma gondii-induced T-cell suppression through an IL-2-related mechanism but independently of IL-10.Eur J Immunol. 2011 Dec;41(12):3529-41.
Teodorczyk-Injeyan JA, McGregor M, Ruegg R, Injeyan HS.
Interleukin 2-regulated in vitro antibody production following a single spinal manipulative treatment in normal subjects.Chiropr Osteopat. 2010 Sep 8;18:26. doi: 10.1186/1746-1340-18-26. PMID: 20825650; PMCID: PMC2945351.
Thorén FB, Romero AI, Brune M, Hellstrand K.
Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.Expert Opin Biol Ther. 2009 Sep;9(9):1217-23.
Thurman GB, Maluish AE, Rossio JL et al.
Comparative evaluation of multiple lymphoid and recombinant human interleukin-2 preparations.J Biol Response Mod. 1986 Feb;5(1):85-107. PMID: 3514800.
Titov K.S., Kiselevskii M.V., Demidov L.V., Mikhailova I.N., Shubina I.Z., Rodionova L.M., Sinel’Nikov I.E., Topol’ K.Y., Gritsai A.N.
Use of recombinant interleukin-2 for intrapleural therapy of tumor-associated pleurisy.
Bulletin of Experimental Biology and Medicine. 2009. Т. 148. № 5. С. 794-796
Tolstoy A.D., Smirnov M.N., Andreev M.I., Sopia R.A.
First experience in treating severe acute pancreatitis with recombinant human interleukin-2.
Int. J. Immunorehabilitation. 2000. V. 2. № 3. P. 126.
Totolian A., Galkina O., Zueva Ye. et al.
Clinical and immunological effects of IL-2 (Roncoleukin) therapy in patients with surgical sepsis (the double-blind study results).
Proceedings of 6th Intern. Expert Forum on Immunotherapy and Gene Therapy. Florence, 1998. P.60.
Totolian A., Lavrenova G., Galkina O. et al.
Local immunotherapy of purilent sinusitis by recombinant human interleukin-2.
5th Word Condress on Trauma, Shock, Inflammation and Sepsis. Pathophisiology, Immune Consequences and Therapy. Munich (Germany, 2000. Proceedings, ed. Eugen Faist, 2000. P. 307-311.
Tsybin Ju.N., Tarelkina M.N., Gromov M.I.,
Immunoreabilitation in severe trauma and surgery sepsis with the Roncoleukin (human interleukin-2 from yeast).
Intern. J. Immunorehabilitation. 1994. № I. Suppl. P. 359-360.
Tyrinova T, Leplina O, Mishinov S et al.
Defective Dendritic Cell Cytotoxic Activity of High-Grade Glioma Patients’ Results from the Low Expression of Membrane TNFα and Can Be Corrected In Vitro by Treatment with Recombinant IL-2 or Exogenic Double-Stranded DNA.J Interferon Cytokine Res. 2018 Jul;38(7):298-310.
Tzannis S.T., Hrushesky W.J., Wood P.A., Przybycien T.M.
Irreversible Inactivation of Interleukin 2 in a Pump-Based Delivery Environment.Proc Natl Acad Sci USA. 1996 May 28;93(11):5460-5. doi: 10.1073/pnas.93.11.5460.
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.